167 related articles for article (PubMed ID: 38265522)
21. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN
Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295
[TBL] [Abstract][Full Text] [Related]
22. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
[TBL] [Abstract][Full Text] [Related]
23. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.
Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD
Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910
[TBL] [Abstract][Full Text] [Related]
24. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
25. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
[TBL] [Abstract][Full Text] [Related]
26. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
[TBL] [Abstract][Full Text] [Related]
27. Survival and Prognostic Factors of Adult Intracranial Ependymoma: A Single-institutional Analysis of 236 Patients.
Zhao F; Wu T; Wang LM; Zhang J; Zhang H; Li SW; Zhang S; Li P; Wang B; Luo L; Liu PN
Am J Surg Pathol; 2021 Jul; 45(7):979-987. PubMed ID: 33739788
[TBL] [Abstract][Full Text] [Related]
28. Morphology-based molecular classification of spinal cord ependymomas using deep neural networks.
Schumann Y; Dottermusch M; Schweizer L; Krech M; Lempertz T; Schüller U; Neumann P; Neumann JE
Brain Pathol; 2024 Jan; ():e13239. PubMed ID: 38205683
[TBL] [Abstract][Full Text] [Related]
29. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
30. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
31. MRI-based texture analysis for differentiate between pediatric posterior fossa ependymoma type A and B.
Cui Z; Ren G; Cai R; Wu C; Shi H; Wang X; Zhu M
Eur J Radiol; 2022 Jul; 152():110288. PubMed ID: 35567893
[TBL] [Abstract][Full Text] [Related]
32. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B.
Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725
[TBL] [Abstract][Full Text] [Related]
33. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
34. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
Benesch M; Mynarek M; Witt H; Warmuth-Metz M; Pietsch T; Bison B; Pfister SM; Pajtler KW; Kool M; Schüller U; Pietschmann K; Juhnke BO; Tippelt S; Fleischhack G; Schmid I; Kramm CM; Vorwerk P; Beilken A; Classen CF; Hernáiz Driever P; Kropshofer G; Imschweiler T; Lemmer A; Kortmann RD; Rutkowski S; von Hoff K
Oncologist; 2019 Sep; 24(9):e921-e929. PubMed ID: 30850560
[TBL] [Abstract][Full Text] [Related]
35. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
37. Treatment implications of posterior fossa ependymoma subgroups.
Ramaswamy V; Taylor MD
Chin J Cancer; 2016 Nov; 35(1):93. PubMed ID: 27846874
[TBL] [Abstract][Full Text] [Related]
38. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.
Kresbach C; Neyazi S; Schüller U
Brain Pathol; 2022 Jul; 32(4):e13068. PubMed ID: 35307892
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
[TBL] [Abstract][Full Text] [Related]
40. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
